Windward Bio Group AG

expected

Not yet set

status

Filed with SEC

Industry

Biological Products, (No Diagnostic Substances)

Incorporated in

Switzerland

Underwriters (from filing)

Jefferies LLC, TD Securities (USA) LLC, UBS Securities LLC

Overview

— AI-generated from the filing, see note below

Business overview

WINDWARD BIO GROUP AG is a clinical-stage biotechnology company focused on developing ultra-long-acting antibody medicines aimed at treating serious respiratory and dermatologic diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. The company targets a significant market opportunity, estimating a combined peak market potential of $60 billion for biologic therapies in these disease areas. The primary product candidates are WIN378, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), and WIN027, a bispecific antibody targeting both TSLP and interleukin-13 (IL-13).

Revenue model

Not disclosed in the provided filing text.

Competitive strengths

Development of ultra-long-acting antibody treatments allowing for less frequent dosing.
Targeting clinically validated disease pathways (TSLP and IL-13).
Enhanced target affinity and low immunogenicity.
Potential for improved clinical outcomes compared to existing therapies.

Risk factors

Limited operating history may hinder evaluation and prediction of future success.
Significant financial losses and need for additional capital to support operations.
No products approved for commercial sale as of yet.
Potential unforeseen expenses and delays in product development.
Dependence on successful clinical trial outcomes for product candidates.

Use of proceeds

Not disclosed in the provided filing text.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

Underwriters on the deal include Jefferies LLC, TD Securities (USA) LLC, UBS Securities LLC. It is classified under Biological Products, (No Diagnostic Substances).

Related IPO lists

Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Windward Bio Group AG.

Biotech IPOs Jefferies LLC IPOs UBS Securities LLC IPOs

Embed this company

Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.

Iframe — WordPress / Ghost / Notion / Webflow

<iframe src="https://www.discoveripo.com/embed/windward-bio-group" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Windward Bio Group AG — DiscoverIPO"></iframe>

Dark by default. For a light background, use https://www.discoveripo.com/embed/windward-bio-group?theme=light as the src instead.

Share image — Substack, email, anywhere

https://www.discoveripo.com/ipo/windward-bio-group/opengraph-image

Attribution text

Windward Bio Group AG IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/windward-bio-group?utm_source=embed&utm_medium=text&utm_campaign=windward-bio-group

Track this IPO

Get emailed when Windward Bio Group AG's terms, price, or expected date change — no weekly noise, just this company.

Where this data comes from

Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Oct 30, 2026.

View the original filing on SEC EDGAR →

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.